GeneOne Life Science, Inc. (KRX:011000)

Market Cap	106.99B -39.2%
Revenue (ttm)	17.12B -54.0%
Net Income	-45.40B
EPS	-536.46
Shares Out	90.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,937,377
Open	1,194.00
Previous Close	1,177.00
Day's Range	1,105.00 - 1,380.00
52-Week Range	618.00 - 4,020.00
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	May 28, 2026

About GeneOne Life Science

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1976
• Employees: 41
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 011000

Financial Performance

In 2025, GeneOne Life Science's revenue was 23.04 billion, a decrease of -35.49% compared to the previous year's 35.72 billion. Losses were -51.85 billion, 6.83% more than in 2024.